Muscular dystrophies are a genetically and phenotypically heterogeneous group of degenerative muscle diseases. A subset of them are due to genetic deficiencies in proteins which form the dystrophin-associated complex at the membrane of the myofibers. In this report, we utilized recombinant adeno-associated virus containing a U7 cassette carrying an antisense sequence aimed at inducing exon skipping of the dystrophin gene or containing the a-sarcoglycan gene to alleviate the dystrophic phenotype of the mdx and Sgca-null mice, respectively. As these diseases are characterized by cycle of degeneration/regeneration, we postulated that a reporter gene coadministered at the time of the treatment would make it possible to follow the extent of muscle repair. We observed that the murine secreted alkaline phosphatase (muSeAP) level was very much lower in these animal models than in normal mice. Upon treatment of the dystrophic muscle by gene transfer, the level of muSeAP was restored and correlated with the expression of the therapeutic transgene and with the level of muscle improvement. The system described here provides a simple and noninvasive procedure for monitoring the outcome of a therapeutic strategy involving cell survival.
Introduction
Muscular dystrophies are a group of more than 25 inherited disorders characterized by progressive loss of muscle fibers associated with muscle weakness. Genetic definition and further characterization of these disorders has led to the demonstration that, in many cases, they are due to disruption of the linkage between the internal cytoskeleton of the muscle fiber and the extracellular matrix, and has established the pivotal role of the dystrophin-associated glycoprotein complex (DGC) in maintaining this linkage. 1 For example, dystrophin, a 427 kDa protein which links the F-actin to transmembrane components of the DGC, is mutated in the X-linked Duchenne muscular dystrophy (DMD) and in the milder Becker muscular dystrophy (BMD), while the transmembrane glycoproteins, a-, b-, g-and dsarcoglycans, are mutated in several recessive forms of limb-girdle muscular dystrophies (LGMD2D, E, C and F, respectively). [2] [3] [4] [5] [6] [7] [8] These disorders are characterized clinically by an increase in serum creatine kinase level and an involvement of specific groups of muscles, especially those of proximal part of the limbs, that is often associated with pseudo-hypertrophy of the calves. The dystrophic features in muscle biopsies present as fibers with central nucleation reflecting regeneration, inflammatory infiltrates, fiber splitting, fibrosis and necrosis. 9 To date, the management of these disorders is mainly supportive (orthopedic assistance, mechanical ventilation, surgery for contractures) and effective treatment remains a tremendous challenge. The field of experimental therapeutics has been in fact an intense and active area of research in recent years. Indeed, an impressive list of different innovative strategies, encompassing pharmacological, cell-based, gene transfer-based and improvement-of-muscle-strength approaches, has been investigated in animal models of muscular dystrophies and especially in the dystrophin-deficient mdx mouse. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The most promising strategies have used recombinant adeno-associated virus (AAV) vectors to deliver a therapeutic DNA into the muscle either by intramuscular injection or systemic delivery. For dystrophin, this has been carried out in the form of micro-dystrophin or of a modified U7 snRNA carrying an antisense sequence aimed at restoring the translational frame by inducing exon skipping and, for sarcoglycans, in the form of a normal version of the corresponding cDNA. [20] [21] [22] [23] [24] [25] Before a therapeutic strategy can be implemented in a clinical trial, it is necessary to obtain objective indicators of therapeutic efficacy, especially since the approaches tested may have different outcomes and may correct some but not necessarily all the pathophysiological parameters. In the case of dystrophin or sarcoglycan deficiencies, a therapeutical benefit can be characterized by the restoration of the DGC at the sarcolemma, a correction of the dystrophic muscle histopathology or recovery of membrane integrity, and eventually by an increase in specific force and a decreased susceptibility to contraction-induced injury. 26 However, evaluation of all these parameters necessitates tissue removal and therefore can only be performed at the end point of the experiments. They may also require burdensome analytical procedure such as morphometrical investigation or expensive specialized apparatus for functional evaluation. The invasiveness of these procedures makes them highly demanding in terms of the number of animals tested in order to get a kinetic picture of the recovery. The effort to improve treatment efficiency and to provide proof of concept would obviously benefit from a noninvasive means of assessment. Considering that muscular dystrophies are characterized by cycles of necrosis and regeneration, we hypothesized that the expression of a reporter gene injected in the muscle would reflect the extent of cell survival over time and, therefore, if administered at the time of the implementation of a therapeutic strategy, would represent a means of following the recovery of the muscle. To test this hypothesis, we chose to use murine secreted alkaline phosphatase (muSeAP), because this very sensitive and non-immunogenic reporter protein is easily measured in blood samples. 27 We observed that the muSeAP level obtained after injection into the muscle via AAV was very much less in animal models deficient in dystrophin (mdx mice) or in a-sarcoglycan (Sgca-null mice) than in normal mice. Upon treatment of the dystrophic muscle by gene transfer experiment, the level of muSeAP is restored and is correlated with the expression of the therapeutic transgene and with the level of muscle improvement, validating the use of this reporter protein as a tool for evaluation of the therapy of muscular dystrophies.
Results

muSeAP reporter expression is reduced in animal models of muscular dystrophies
We constructed an AAV2/1 vector encoding muSeAP under the control of a truncated muscle creatine kinase (MCK) (CK6) promoter (Figure 1a) . 28 The use of a muscle-specific promoter ensures that the muSeAP measured in blood reflects the expression from muscle fibers. To test the hypothesis that muSeAP expression would decrease over time in dystrophic compared to wild-type mice due to loss of myofibers during necrosis/ regeneration cycles, viral preparations of this vector were injected into the quadriceps muscle of mdx and Sgca-null mice and their corresponding controls (see Materials and methods section). The serum level of muSeAP was analyzed in blood samples 42 days after injection, showing that it was largely reduced in both dystrophic models (Figure 1b) . Concentration of muSeAP was 19.3-fold lower in mdx mice compared to C57bl/10 controls and 28.2-fold lower in Sgca-null mutants than in C57bl/6 controls. This decrease was significantly higher in the Sgca-null mutant compared to mdx, possibly reflecting an elevated rate of myofiber turnover in this model.
Application of AAV gene transfer protocols to rescue mdx and Sgca dystrophic muscles
To assess whether a therapeutic intervention could improve muSeAP secretion, we introduced corrective sequences into mdx and Sgca-null muscles. For mdx phenotype correction, we administered an AAV2/1 vector expressing antisense sequences through a U7 small nuclear modified RNA (AAV-U7-SD23-BP22; Figure 2a , upper panel). 21 The antisense sequences mediate exon skipping of the mutated exon 23 of the mdx dystrophin and restore the translational frame of the mRNA, leading to the expression of a functional dystrophin and correction of the muscular dystrophy. For Sgca-null phenotype correction, we chose to express a-sarcoglycan in muscle by means of intramuscular injection of an AAV2/1 vector carrying the coding sequence under the control of a MCK promoter fragment (Figure 2a, lower panel) .
Anesthetized 7-to 10-week-old mice received a single intramuscular injection into the quadriceps muscle (6 Â 10 11 viral genome (vg) for AAV2/1-U7-SD23-BP22 and 1.5 Â 10 10 for AAV2/1-MCK-Sgca vectors). We chose to inject this large muscle to investigate the therapeutic efficacy of both strategies, considering that, in the following experiments where the therapeutic and reporter vectors would have to be coadministered, we would have to inject a volume that would exceed the capacity of smaller muscles. Mice were euthanatized 63 days postinjection. The day before, mice received an intraperitoneal injection of Evans blue, a dye that penetrates degenerating fibers. 29 Frozen sections of quadriceps muscles were stained with hematoxylin and eosin (H&E) (Figure 2b and d) . Dystrophin or a-sarcoglycan expression was determined by immunochemistry and muscle damage was evaluated by Evans blue uptake (Figure 2c 
Muscle recovery stabilizes muSeAP secretion
Having assessed that both treatments ensured a sustained and efficient improvement of the quadriceps muscle, we examined whether they would improve muSeAP secretion. In the first step, we verified whether muSeAP secretion would not be influenced by the expression level of a-sarcoglycan achieved by AAV2/ 1-MCK-Sgca injection or by the injection of U7snRNAs. For this purpose, wild-type mice were injected with AAV2/1-MCK-muSeAP together with AAV2/1-MCK-Sgca, AAV2/1-U7-SD23-BP22 or empty AAV2/1 vector, and muSeAP secretion in the bloodstream was quantified. All mice, regardless of the treatment, had superimposable muSeAP secretion amounts ( Figure 3a ).
In the second step, we coinjected the therapeutic AAV2/1 vectors together with the AAV2/1-MCKmuSeAP vector intramuscularly in the corresponding models. The day of injection and every week afterward for 2 months, blood samples were taken from mice and analyzed for muSeAP secretion. Figure 3b presents results obtained in mdx mice injected with AAV2/1-U7-SD23-BP22 or with PBS. At each point during the course of the experiment starting at day seven, the blood level of muSeAP was higher in mice coinjected with AAV2/1-U7-SD23-BP22 than in nontreated mice. Furthermore, whereas the level of muSeAP expression increased constantly in mice injected with AAV2/1-U7-SD23-BP22, muSeAP secretion seem to decline 50 days after injection in nontreated mice. At the end of the experiment (at day 63), the level of muSeAP was 308% greater in mice injected with AAV2/1-U7-SD23-BP22 than in nontreated mice. At this point, the value represents 20% of the level obtained in wild-type mice (Figure 3a) . In Sgca-null mutant mice, injection of AAV2/1-MCK-Sgca vector also increased muSeAP secretion constantly as compared with mice injected with empty AAV2/1 vector ( Figure 3c ). As seen in the mdx experiment, the level of muSeAP was higher in mice injected with AAV2/1-MCK-Sgca vector compared to nontreated mice for each point analyzed. In AAV2/1-MCK-Sgca vector-injected mice, the muSeAP level in blood at day 63 reached 363% of the value obtained in dystrophic animals injected with PBS, and 23.6% of the value obtained in wild-type mice (Figure 3a) . (c, e) Serial sections were stained with antibodies against dystrophin or a-sarcoglycan (green). To evaluate fiber viability, Evans blue dye was injected intraperitoneally 12 h before the killing, allowing the detection of necrotic fibers (red). All sections were counterstained with DAPI (blue). In (b, c), the right panels represent muscle from AAV2/1-U7-SD23-BP22-treated mdx mice and the left panels the nontreated mdx mice. In (d, e), the right panels represent muscle from AAV2/1-MCK-Sgca-treated Sgca-null mutant mice and the left panels, the nontreated Sgca-null mutant (scale bars represent 40 mm).
Noninvasive monitoring of therapeutic gene transfer M Bartoli et al muSeAP expression is correlated with the recovery of the fibers At the endpoint of the above experiments, quadriceps muscles were removed and examined for dystrophin or a-sarcoglycan expression by immunochemistry, Evans blue uptake and muSeAP activity using an alkaline phosphatase substrate. Comparison of the dystrophin and muSeAP staining indicated a high degree of colocalisation (Figure 4a and b) . Similar results were seen in mice treated with AAV2/1-MCK-Sgca (Figure 4c and d). Transgene expression is mainly concentrated in one region of the quadriceps muscle. In this region, most of the fibers are transduced due to the high efficiency of the AAV1 serotype. [30] [31] [32] Noticeably, no muSeAP activity was detected in myofibers not expressing a-sarcoglycan, despite more vg copies of AAV2/1-MCK-muSeAP being injected compared to AAV2/1-MCK-Sgca. It is therefore possible that myofibers infected only with muSeAP have disappeared from the muscle.
The Figure 5a ). Using these primers, we measured the level of dystrophinskipped mRNA in wild-type mice and mdx mice infected or not with AAV2/1-U7-SD23-BP22 (Figure 5b ). The amount of muSeAP measured in the blood of the individual animal correlated significantly with the level of dystrophin exon skipping (r 2 ¼ 0.8087 with a P-value o0.05) or a-sarcoglycan expression (r 2 ¼ 0.7472 with a P-value o0.01).
Discussion
In this study, we have demonstrated, by coadministration of the muSeAP gene together with the therapeutic gene in the muscles of two animal models of muscular dystrophy, that the level of muSeAP obtained in blood reflects the extent of muscle reparation. This proof-ofprinciple experiment demonstrates the potential of this noninvasive measurement as a tool in evaluating the efficacy of therapeutic strategies.
The two diseases investigated here are characterized by perturbation of the DGC, an important complex which protects the sarcolemma from contraction-induced stresses. [33] [34] [35] It has been shown that deficiency in these proteins makes the membrane vulnerable and renders it prone to tears during contraction. [36] [37] [38] This membrane leakage induces abnormal calcium influx followed by activation of the ubiquitous calpains, leading to an excess of unwanted and untimely proteolysis, and finally necrosis of the muscle fiber. [39] [40] [41] Accordingly, the high numbers of central nuclei found in both models indicate an ongoing cycle of necrosis and regeneration. The two treatments used alleviated the pathophysiological signs, as demonstrated by improved histology and Evans blue dye exclusion. The expression of the antisense sequence aimed at skipping exon 23 of the dystrophin gene restores the reading frame of the transcript and ensures the production of a functional, albeit truncated, protein that localizes correctly at the sarcolemma, and the expression of a normal version of the a-sarcoglycan gene ensures production of a normal protein that localizes at the right place in the a-sarcoglycan-null fiber. It should Noninvasive monitoring of therapeutic gene transfer M Bartoli et al be noted that, for the latter approach, we used a MCK promoter fragment derived from a previously characterized construct called CK3. AAV-mediated transfer of a-sarcoglycan has been previously attempted with a ubiquitous CMV promoter in another a-sarcoglycandeficient model. 22 Although a short-term rescue of the muscle was obtained, the cytotoxicity induced by the high level of expression from this promoter led to an early disappearance of the expression of a-sarcoglycan. Muscle expression driven by the MCK promoter was thought to represent only a fraction of the value obtained with the ubiquitous CMV promoter, but it is sufficient to ensure a correct production of a-sarcoglycan. 28 Furthermore, it is not associated with cytotoxicity, as demonstrated by the sustained expression of the protein in the model and by the equivalent muSeAP expression obtained over time in normal treated and nontreated mice. Our data confirm the suggestion made by Hauser et al. 28 and Cordier et al. 42 that the expression level of a transgene can be a critical parameter in gene transfer to avoid adverse effects, and further emphasizes the rationale of using a muscle-specific promoter in therapeutic strategies for treating muscular dystrophies. However, this is not an issue for the exon-skipping strategy used to treat dystrophin-deficient muscle, as it results in the partial correction of a transcript naturally produced by the endogenous promoter. Both of these resulted in the restoration of the DGC function, as indicated by Evans blue dye exclusion. The reintroduction of the corresponding protein seems to stabilize the fiber, protecting it from contraction-induced damage and subsequent necrosis, with the consequence of stopping the cycles of degeneration regeneration. As we showed, this will benefit the muSeAP expression in coadministration experiments, since the survival of the fiber ensures persistence of the vector. Conversely, fibers in nontreated muscles still can die and the expression of muSeAP is gradually lost. The measured level of Noninvasive monitoring of therapeutic gene transfer M Bartoli et al muSeAP will, therefore, reflect the number of rescued fibers. The increase in muSeAP concentration observed when mice were coinjected at the same time with the muSeAP vector and the therapeutic vectors argues against an immune response that could have arisen against the muSeAP protein as the inflammatory environment was initially the same in treated and untreated dystrophic muscles. Injection of a muSeAP reporter vector is a simple method of assessing the therapeutic efficiency. It involves little additional work, since the muSeAP vector can be coinjected with the therapeutic transgene in any experiment and therefore this procedure can be incorporated into a battery of tests. It offers several advantages over other in vivo assessments of therapeutic efficacy. First, muSeAP is easily measured in a blood sample with a high level of sensitivity. 27 As a consequence, the efficacy of a putative treatment can be assessed rapidly. Second, the procedure is noninvasive, reducing the number of animals needed, especially for a kinetic evaluation, which facilitates long-term monitoring. Grip force testing and measurement of serum creatine kinase level are also noninvasive. 43 However, identification of an improvement would necessitate the treatment of a maximum number of muscles to see any effect. Another noninvasive procedure pioneered by the group of Straub is magnetic resonance imaging. 44 However, this procedure necessitates expensive equipment and highly trained personal. Third, the outcome in individual animals can be followed rather than averaging results from groups, increasing the power of statistical analysis. In addition, these measurements could help to define the minimal therapeutical dose. It may be possible to reach a plateau that would correspond to a maximum efficiency coinciding with a complete restoration of the muscle. If this level can be demonstrated as nontoxic, there would be good prospects for clinical trials.
Considering that the level of muSeAP will reflect the survival of the cell, it has the potential to estimate cell half-life, as, for example, in muscle during aging, and to evaluate the efficiency of therapy in any muscular dystrophy where necrosis occurs. It could help to evaluate and define the best experimental conditions in terms of definition of the coinjected vector and means of delivery. For the latter point, it should be noted that this procedure can be used in systemic delivery approaches, provided that the promoter used is specific to the targeted tissue. It may well be applicable to other diseases, even nongenetic, in other organ system where necrosis appears in the process of the disease. Inversely, it may also be used when a treatment is aimed at destruction of unwanted cells as in cancer.
Materials and methods
Vector construction
The plasmid pAAV-MCK-muSeAP was constructed by subcloning an XhoI-NotI fragment containing the muSeAP coding sequence (obtained from the pVT20 plasmid, a gift from Vincent Thuiller) into an AAV-based pSMD2-derived vector. 27, 45 The latter vector carries a truncated MCK CK6 promoter previously described. 28 The plasmid pSub-hSgca used to prepare the AAV2/1-MCK-Sgca vector was a gift from Dr Lee Sweeney (University of Pennsylvania, Philadelphia, USA). The coding sequence of the human a-sarcoglycan is inserted between the AAV2 inverted terminal repeats (ITR) and is placed under the control of an MCK promoter fragment which contains the region À2155 to +7 base pairs from the transcription initiation site. 23 The pAAV-U7-SD23-BP22 carrying antisense sequences against splicing sequences of the murine dystrophin exon 23 has been previously described. 21 
Recombinant AAV1 vector production
Recombinant AAV viral stocks were produced by the triple transfection method as described previously. 46 Briefly, 293HEK cells were cotransfected with 25 mg of the cis-acting plasmid (pAAV-MCK-muSeAP, pSubhSgca or pAAV-U7-SD23-BP22), 12.5 mg of the transcomplementing rep-cap1 (pLT-RCO 2 ), and adenovirus (pXX6) plasmids. 31, 47 Vector particles were harvested 3 days post-transfection and purified through two sequential CsCl gradients and dialyzed against PBS. The physical particle number of each preparation was determined by dot blot hybridization with a specific probe. 48 The corresponding titers were, for AAV2/1-MCK-muSeAP: 1.54 Â 10 12 vg/ml, for AAV2/1-MCKSgca: 1.99 Â 10 11 vg/ml and for AAV2/1-U7-SD23-BP22: 8 Â 10
12 vg/ml. 
In vivo vector delivery into muscle tissue
A murine knockout for a-sarcoglycan was obtained from K Campbell (Howard Hughes Medical Institute, Iowa City, IA, USA). The construction and characterization of this model has been previously described. 37 The dystrophin-deficient mdx model and the normal controls, C57Bl/6 and C57Bl/10, were purchased from Charles River Laboratories (Les Oncins, France). Mice of specified age were used for intramuscular injection of recombinant AAV. All mice were handled according to the European guidelines for the humane care and use of experimental animals.
Anesthetized (ketamine/xylazine) 7-10-week-old male mice were injected with either 25 ml (4 Â 10 10 vg) of rAAV2/1-MCK-muSeAP alone or 100 ml of a mixture of rAAV2/1-MCK-muSeAP (4 Â 10 10 vg) and rAAV2/1-MCK-Sgca (1.5 Â 10 10 vg) or 100 ml of a mixture of rAAV2/1-MCK-muSeAP (4 Â 10 10 vg) and rAAV2/1-U7-SD23-BP22 (6 Â 10 11 vg) in the left quadriceps muscle. At 1 day prior to the end point of the experiment, the mice were injected intraperitoneally with Evans blue dye (1 mg/g of body weight). The following day, mice were killed and the quadriceps muscles were removed and quickly frozen in liquid nitrogen-cooled isopentane. Blood samples were obtained every week by retro-orbital puncture of anesthetized animals.
Determination of muSeAP secretion
Detection of alkaline phosphatase activity was carried out with the Phospha-Light kit (Tropix Perkin-Elmer) following the manufacturer's instructions except for the following modifications. In all, 15 ml of plasma was diluted in 45 ml of 1 Â dilution buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl) and heated at 651C for 5 min and then cooled down to 41C in a PCR block thermocycler. Then, 50 ml of diluted sample was incubated for 5 min at room temperature with 50 ml of assay buffer (1 M diethanolamine (pH 10.5-11), 1 mM MgCl 2 , 10 mM L-homoarginine) before adding 50 ml of reaction buffer (CSPD substrate with Emerald enhancer). The reaction mixture was incubated for 20 min at room temperature before chemiluminescence measurement (10 s per well) in an MLX microtiter plate luminometer (Dynex).
Histological and immunofluorescence analysis
Serial cryosections (8 mm thickness) prepared from frozen muscles were dried and then rehydrated in PBS. For detection of alkaline phosphatase activity, cryosections were fixed in 0.5% glutaraldehyde for 10 min and washed twice in PBS. The sections were incubated at 651C for 30 min to inactivate endogenous alkaline phosphatase activity, washed once in PBS and overlaid with 0.5 ml of a solution containing 0.165 mg of 5-bromo-4-chloro-3-indoyl phosphate (BCIP) and 0.33 mg of nitroblue tetrazolium (NBT) per ml in 100 mM Tris-HCl, pH 9.5, 100 mM NaCl and 50 mM MgCl 2 at 371C for 30 min (NBT/BCIP Ready-to-Use tablets, Roche). After sufficient color had developed, the sections were washed with H 2 O, and the SeAP-expressing fibers visualized by microscopy. Digital images were captured using a CCD camera and processed using Histolab software (Microvision, Evry, France).
Polyclonal anti-a-sarcoglycan antibody was raised against the CTGERLPPRVDSAQ peptide at the C-terminus of the protein. For the immunofluorescent staining, unfixed cryosections were dried and overlaid for 1 h at room temperature with a 1:1000 dilution in PBS of the polyclonal antibody against a-sarcoglycan. After washes, the sections were incubated with goat anti-rabbit secondary antibodies conjugated to Alexa488 fluorochrome (A-11070, Molecular Probes) at 1:1000 dilution in PBS for 1 h at room temperature. Dystrophin was revealed with monoclonal antibody NCL-Dys2 (Novocastra) using a Vector MOM immunodetection kit (Vector Laboratories, Burlingame, CA, USA). Sections were mounted in DAPI containing Vectashield (Vector Laboratories). Samples were examined under a Leica confocal fluorescent microscope. Evans blue-positive fibers were revealed by fluorescence excitation at 633 nm. The final images represent an assembly of several images taken using a motorized stage at an original Â 40 magnification.
Quantitative RT-PCR
Total RNA was extracted from muscles by the Trizol method (Invitrogen) after pulverization using a Fast Prep FP120 apparatus (Bio101). Residual DNA was removed from the samples using the Free DNA kit (Ambion). A measure of 1 mg of RNA was reverse-transcribed using random hexamers according to the protocol Superscript II first-strand synthesis system for RT-PCR (Invitrogen). Real-time PCR was performed using ABI PRISM 7700 system (PE biosystems) with 0.2 mM of each primer and 0.1 mM of the probe according to the protocol Absolute QPCR Rox Mix (ABgene). The primer pairs and Taqman probe used for a-sarcoglycan amplification were: 920ha-sarco. 
Statistical analysis
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